Munich (Germany) and Hyderabad (India), January 29, 2009 – GVK Biosciences (GVK BIO) and
CRELUX announced today that they have set-up a highly robust fragment-based drug discovery
platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance
structural biology technologies together with GVK BIO’s mature computer-assisted drug design
(CADD) tools and other components of its drug discovery & development engine, encompass all
steps from challenging targets to novel drug candidates.
CRELUX and GVK BIO will provide seamless integration of all aspects of structure-based drug
design for the biopharmaceutical industry and furnishes accelerated timelines for moving
molecules from concept into the clinic at an optimal cost. Fragment-based Drug Design (FBDD)
helps in visualizing binding modes and hence rationalizes an accelerated SAR allowing efficient
lead optimization through CADD. CRELUX will leverage its capabilities of all aspects of
multifaceted structural studies towards X-ray elucidation of fragment or lead target complexes,
whereas GVK BIO will perform all discovery chemistry and biology work including in silico, in
vitro and in vivo studies as well as activities necessary to ensure pre-clinical candidate
“Collaborating with a renowned life-sciences service provider like GVK BIO in a fast emerging
competitive area like fragment-based drug discovery is a strong appreciation of our high quality
services. Together we have generated a truly one-stop-shop from target-to-IND and support
our customers with comprehensive drug discovery services”, commented Dr. Michael Schäffer,
CEO of CRELUX.
“GVK BIO is committed to further advance the discovery tools and services that are needed to
systematically profit from the enhanced understanding of biochemical pathways and important
molecular target families", said Sven Wagner, Ph.D., Vice President, Discovery Business
Development for GVK BIO.
"With a strong alliance partner like CRELUX, GVK BIO is moving in the direction of its vision of
being a global leader in life-sciences services” said Manni Kantipudi, President, GVK BIO.
About GVK BIO
GVK Biosciences (www.gvkbio.com), Asia’s leading Contract Research Organization, delivers
integrated research services to big Pharma and Biotech companies globally. GVK BIO
accelerates the drug discovery and development process of its customers through science and
innovation. GVK BIO has a diverse customer portfolio including 15 big pharma companies, agri
& life-sciences companies, leading biotechs and academic institutions. Headquartered in
Hyderabad, India, GVK BIO has more than 1,500 employees spread across facilities in
Hyderabad, Chennai, Mumbai and Gurgaon in India.
CRELUX (www.crelux.com) has used its state-of-the-art structural biology platform to solve
more than 320 crystal and co-crystal structures for pharma and biotech companies. This
platform encompasses all steps – from target cloning and expression all the way to highthroughput
protein crystallization and in-house x-ray crystallography.